Skip to main content

About Eligo Bioscience

Written by: Editor
Published on: 4 Oct 2024
Category:

EligoEligo Bioscience is the world leader in microbiome in vivo gene editing and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in immunoinflammation, oncology and infectious diseases driven by the expression of deleterious bacterial genes.

Eligo was founded by Luciano Marraffini (Professor at The Rockefeller University and cofounder of Intellia Therapeutics), Timothy Lu (Professor at MIT, and CEO at Senti

Biosciences), Dr. David Bikard (Professor at Institut Pasteur) and Xavier Duportet (MIT TR35, Young Global Leader, and Termeer Fellow).

Eligo was named a Technology Pioneer by the World Economic Forum and received venture capital funding from Sanofi Ventures, Khosla Ventures, Bpifrance, Seventure Partners and VIVES Partners.